Spots Global Cancer Trial Database for byl719
Every month we try and update this database with for byl719 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | NCT01822613 | Esophageal Squa... | LJM716 BYL719 Paclitaxel Docetaxel Irinotecan | 18 Years - | Novartis | |
| Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | NCT04208178 | Advanced HER2+B... | Alpelisib Alpelisib match... Trastuzumab Pertuzumab | 18 Years - | Novartis | |
| Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer | NCT03706573 | HR+ Advanced or... | alpelisib | 18 Years - | Novartis | |
| A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer | NCT02276027 | Adenocarcinoma ... | BYL719 INC280 LDK378 MEK162 | 18 Years - | Novartis | |
| A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients | NCT01735968 | 3rd Line GIST | ST571 + BYL719 | 18 Years - | Novartis | |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss | NCT04251533 | Triple Negative... | alpelisib placebo nab-paclitaxel | 18 Years - | Novartis | |
| Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | NCT01719380 | Colorectal Canc... | LGX818 Cetuximab BYL719 | 18 Years - | Pfizer | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719 | NCT03138070 | Head and Neck S... | BYL719 | 18 Years - | Lawson Health Research Institute | |
| Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer | NCT02167854 | Breast Cancer | BYL719 LJM716 TRASTUZUMAB | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer | NCT03706573 | HR+ Advanced or... | alpelisib | 18 Years - | Novartis | |
| PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer | NCT01613950 | Stomach Neoplas... | AUY922 BYL719 | 18 Years - | Novartis | |
| Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | NCT01872260 | Breast Cancer | LEE011 Letrozole BYL719 | 18 Years - | Novartis | |
| Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer | NCT04473040 | HR+, HER2-, Adv... | alpelisib | 18 Years - 99 Years | Novartis | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | NCT01300962 | Metastatic Brea... | BMK120 Capecitabine BYL719 Trastuzumab Lapatinib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers | NCT02734615 | Advanced or Met... | LSZ102 LEE011 BYL719 | 18 Years - | Novartis | |
| Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma | NCT02144038 | Relapsed and Re... | LGH447 BYL719 | 18 Years - | Novartis | |
| A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors | NCT01708161 | PIK3CA Mutated ... PIK3CA Amplifie... | BYL719 AMG 479 | 18 Years - | Novartis | |
| BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study | NCT02550743 | Rectal Cancer | BYL719 Capecitabine Radiation | 18 Years - | Brown University | |
| Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer | NCT02537223 | Squamous Cell C... Locoregionally ... | BYL719 Cisplatin Intensity modul... | 18 Years - | University Health Network, Toronto | |
| A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients | NCT01735968 | 3rd Line GIST | ST571 + BYL719 | 18 Years - | Novartis | |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss | NCT04251533 | Triple Negative... | alpelisib placebo nab-paclitaxel | 18 Years - | Novartis | |
| A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene | NCT01219699 | Advanced Solid ... Estrogen Recept... | BYL719 Fulvestrant | 18 Years - | Novartis | |
| Phase 1b Trial of BGJ398/BYL719 in Solid Tumors | NCT01928459 | Advanced Solid ... Metastatic Soli... | BGJ398 BYL719 | 18 Years - | Novartis | |
| A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene | NCT01219699 | Advanced Solid ... Estrogen Recept... | BYL719 Fulvestrant | 18 Years - | Novartis | |
| An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy. | NCT02145312 | Recurrent or Me... | BYL719 | 18 Years - | Yonsei University | |
| A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer | NCT02051751 | Neoplasms, Brea... | BYL719 Paclitaxel | 18 Years - | Novartis | |
| Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) | NCT02282371 | Head and Neck S... | Cetuximab BYL719 IMRT (Intensity... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | NCT01719380 | Colorectal Canc... | LGX818 Cetuximab BYL719 | 18 Years - | Pfizer | |
| Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma | NCT02144038 | Relapsed and Re... | LGH447 BYL719 | 18 Years - | Novartis | |
| PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer | NCT01613950 | Stomach Neoplas... | AUY922 BYL719 | 18 Years - | Novartis | |
| Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | NCT01822613 | Esophageal Squa... | LJM716 BYL719 Paclitaxel Docetaxel Irinotecan | 18 Years - | Novartis | |
| Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer | NCT02506556 | Metastatic Brea... | BYl719 | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer | NCT02155088 | Pancreatic Canc... | BYL719 Gemcitabine (nab)-paclitaxe... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | NCT01300962 | Metastatic Brea... | BMK120 Capecitabine BYL719 Trastuzumab Lapatinib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer | NCT04473040 | HR+, HER2-, Adv... | alpelisib | 18 Years - 99 Years | Novartis | |
| BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study | NCT02550743 | Rectal Cancer | BYL719 Capecitabine Radiation | 18 Years - | Brown University | |
| BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer | NCT01870505 | Metastatic or L... | BYL719 Letrozole Exemestane | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719 | NCT03138070 | Head and Neck S... | BYL719 | 18 Years - | Lawson Health Research Institute | |
| Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer | NCT02088684 | Breast Cancer | LEE011 BYL719 fulvestrant BKM120 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
